Hours, not weeks: a new test could speed up lymphoma diagnosis
NCT ID NCT07739849
First seen Jul 31, 2026 ยท Last updated Jul 31, 2026
Summary
This trial tests whether a rapid lab technique called flow cytometry can quickly identify lymphoma from a small lymph node sample. People already undergoing a standard fine needle aspiration for suspected lymphoma will give an extra sample for this test. The goal is to see if this approach can cut the diagnostic time from weeks down to hours, helping patients get answers and treatment faster.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Flow cytometric immunophenotyping on additional fine needle aspiration (FNA) samples
- What this could lead to
- If successful, this could shorten the time to lymphoma diagnosis from weeks to hours, helping patients start treatment sooner and easing anxiety during the diagnostic process.
- What could go wrong
- This is an early-stage diagnostic study, and the technique may not be accurate enough to replace standard biopsy in all cases. Additional testing may still be needed to confirm a lymphoma diagnosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could muscle loss predict blood cancer outcomes?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare